Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers

International Journal of Hypertension

Volumn 2012, Issue , 2012, Pages

  Andersson, Hanna ^a   Hallberg, Mathias ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ALDOSTERONE; ALISKIREN; AMINOPEPTIDASE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; AZILSARTAN MEDOXOMIL; BENAZEPRIL; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HFI 419; HFI 435; INSULIN REGULATED AMINOPEPTIDASE; INSULIN REGULATED AMINOPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; PERINDOPRIL; PNB 0408; PROTEINASE INHIBITOR; QUINAPRIL; RAMIPRIL; RENIN; RENIN INHIBITOR; SARALASIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGEUSIA; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN FUNCTION; COGNITION; CONFORMATIONAL TRANSITION; CYCLIZATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HYPERTENSION; HYPOTHESIS; LEARNING; MEMORY CONSOLIDATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STRUCTURE ACTIVITY RELATION; VASODILATATION;

EID: 84871843262     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.1155/2012/789671     Document Type: Review

References (187)

1. Kastin A. J., Zadina J. E., Olson R. D., Banks W. A., The history of neuropeptide research: version 5.a. Annals of the New York Academy of Sciences 1996 780 1 18 2-s2.0-0029951057 10.1111/j.1749-6632.1996.tb15107.x (Pubitemid 26196965)
2. Hallberg M., Nyberg F., Neuropeptide conversion to bioactive fragments-an important pathway in neuromodulation. Current Protein and Peptide Science 2003 4 1 31 44 2-s2.0-0037302811 10.2174/1389203033380313 (Pubitemid 36131669)
3. Chai S. Y., Fernando R., Ye S., Peck G. R., Albiston A. L., Hooper N. M., Lendeckel U., Insulin-regulated aminopeptidase, in Proteases in biology and disease. Aminopeptidases in Biology and Disease 2004 New York, NY, USA Kluwer Academic/Plenum Publishers 61 81
4. Hallberg M., Le Greves P., Nyberg F., Lendeckel U., Hooper N. M., Neuropeptide processing. Proteases in Biology and Disease, Proteases in the Brain 2005 New York, NY, USA Springer Science 203 234
5. Johnston C. I., Risvanis J., Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues. American Journal of Hypertension 1997 10 12 306S 310S 2-s2.0-0031418447 10.1016/S0895-7061(97)00388- 9 (Pubitemid 28133254)
6. Fyhrquist F., Saijonmaa O., Renin-angiotensin system revisited. Journal of Internal Medicine 2008 264 3 224 236 2-s2.0-49349107302 10.1111/j.1365-2796. 2008.01981.x
7. Blair-West J. R., Carey K. D., Denton D. A., Madden L. J., Weisinger R. S., Shade R. E., Possible contribution of brain angiotensin III to ingestive behaviors in baboons. American Journal of Physiology 2001 281 5 R1633 R1636 2-s2.0-0035194740
8. Wright J. W., Miller-Wing A. V., Shaffer M. J., Higginson C., Wright D. E., Hanesworth J. M., Harding J. W., Angiotensin II(3-8) (ANG IV) hippocampal binding: potential role in the facilitation of memory. Brain Research Bulletin 1993 32 5 497 502 2-s2.0-0027317723 10.1016/0361-9230(93)90297-O (Pubitemid 23251954)
9. Lee J., Chai S. Y., Mendelsohn F. A. O., Morris M. J., Allen A. M., Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LVV-hemorphin-7. Neuropharmacology 2001 40 4 618 623 2-s2.0-0035092007 10.1016/S0028-3908(00)00188-X (Pubitemid 32209047)
10. Cesari M., Rossi G. P., Pessina A. C., Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases. Journal of Hypertension 2002 20 5 793 799 2-s2.0-0036563250 10.1097/00004872-200205000-00002 (Pubitemid 34913648)
11. Hall K. L., Venkateswaran S., Hanesworth J. M., Schelling M. E., Harding J. W., Characterization of a functional angiotensin IV receptor on coronary microvascular endothelial cells. Regulatory Peptides 1995 58 3 107 115 2-s2.0-0029086764 10.1016/0167-0115(95)00068-M
12. Wright J. W., Harding J. W., Important roles for angiotensin III and IV in the brain renin-angiotensin system. Brain Research Reviews 1997 25 1 96 124 2-s2.0-0031591786 10.1016/S0165-0173(97)00019-2 (Pubitemid 27459723)
13. Pederson E. S., Krishnan R., Harding J. W., Wright J. W., A role for the angiotensin AT4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. Regulatory Peptides 2001 102 2-3 147 156 2-s2.0-0035892226 10.1016/S0167-0115(01)00312-3 (Pubitemid 33135576)
14. De Bundel D., Smolders I., Yang R., Albiston A. L., Michotte Y., Chai S. Y., Angiotensin IV and LVV-haemorphin 7 enhance spatial working memory in rats: effects on hippocampal glucose levels and blood flow. Neurobiology of Learning and Memory 2009 92 1 19 26 2-s2.0-67349263442 10.1016/j.nlm.2009.02.004
15. Ardaillou R., Chansel D., Synthesis and effects of active fragments of angiotensin II. Kidney International 1997 52 6 1458 1468 2-s2.0-0031435757 (Pubitemid 28032049)
16. Jankowski V., Vanholder R., Van Der Giet M., Tölle M., Karadogan S., Gobom J., Furkert J., Oksche A., Krause E., Tran T. N. A., Tepel M., Schuchardt M., Schlüter H., Wiedon A., Beyermann M., Bader M., Todiras M., Zidek W., Jankowski J., Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 2 297 302 2-s2.0-33846417985 10.1161/01.ATV.0000253889.09765.5f (Pubitemid 46143043)
17. Yang R., Smolders I., Vanderheyden P., Demaegdt H., Van Eeckhaut A., Vauquelin G., Lukaszuk A., Tourwé D., Chai S. Y., Albiston A. L., Nahmias C., Walther T., Dupont A. G., Pressor and renal hemodynamic effects of the novel angiotensin a peptide are angiotensin II type 1A receptor dependent. Hypertension 2011 57 5 956 964 2-s2.0-79955479435 10.1161/HYPERTENSIONAHA.110. 161836
18. Banegas I., Prieto I., Vives F., Alba F., de Gasparo M., Segarra A. B., Hermoso F., Durán R., Ramírez M., Brain aminopeptidases and hypertension. Journal of the Renin-Angiotensin-Aldosterone System 2006 7 3 129 134 2-s2.0-33751010469 10.3317/jraas.2006.021 (Pubitemid 44740946)
19. Reudelhuber T. L., The renin-angiotensin system: peptides and enzymes beyond angiotensin II. Current Opinion in Nephrology and Hypertension 2005 14 2 155 159 2-s2.0-15444367989 (Pubitemid 40396869)
20. Saavedra J. M., Brain and pituitary angiotensin. Endocrine Reviews 1992 13 2 329 380 2-s2.0-0026773791 10.1210/er.13.2.329
21. Speth R. C., Brown T. E., Barnes R. D., Wright J. W., Brain angiotensinergic activity: the state of our current knowledge. Proceedings of the Western Pharmacology Society 2003 46 11 15 2-s2.0-0344874562 (Pubitemid 37463421)
22. Unger T., Badoer E., Ganten D., Lang R. E., Rettig R., Brain angiotensin: pathways and pharmacology. Circulation 1988 77 6 I-40 I-54 2-s2.0-0023913168
23. Johnston C. I., Biochemistry and pharmacology of the renin-angiotensin system. Drugs 1990 39 supplement 1 21 31 2-s2.0-0025101253 (Pubitemid 20050793)
24. Ferrario C. M., Chappell M. C., Novel angiotensin peptides. Cellular and Molecular Life Sciences 2004 61 21 2720 2727 2-s2.0-11144297985 10.1007/s00018-004-4243-4 (Pubitemid 40022433)
25. Vauquelin G., Michotte Y., Smolders I., Sarre S., Ebinger G., Dipont A., Vanderbeyden P., Cellular targets for angiotensin II fragments: pharmacological and molecular evidence. Journal of the Renin-Angiotensin-Aldosterone System 2002 3 4 195 204 2-s2.0-0036986979 (Pubitemid 36187374)
26. Pinheiro S. V. B., Simões e Silva A. C., Sampaio W. O., De Paula R. D., Mendes E. P., Bontempo E. D., Pesquero J. B., Walther T., Alenina N., Bader M., Bleich M., Santos R. A. S., Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor mas agonist in the mouse kidney. Hypertension 2004 44 4 490 496 2-s2.0-4644372221 10.1161/01.HYP.0000141438.64887.42 (Pubitemid 39281501)
27. Ferreira A. J., Murca T. M., Fraga-Silva R. A., Castro C. H., Raizada M. K., Santos R. A., New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. International Journal of Hypertension 2012 2012 147825
28. Wright J. W., Mizutani S., Harding J. W., Focus on brain angiotensin III and aminopeptidase A in the control of hypertension. International Journal of Hypertension 2012 2012 124758
29. Khosla M. C., Leese R. A., Maloy W. L., Ferreira A. T., Smeby R. R., Bumpus F. M., Synthesis of some analogs of angiotensin II as specific antagonists of the parent hormone. Journal of Medicinal Chemistry 1972 15 8 792 795 2-s2.0-0015384193
30. Haber E., The role of renin in normal and pathological cardiovascular homeostasis. Circulation 1976 54 6 849 861 2-s2.0-0017141008
31. Brunner H. R., Gavras H., Laragh J. H., Keenan R., Angiotensin II blockade in man by SAR ALA angiotensin II for understanding and treatment of high blood pressure. Lancet 1973 2 7837 1045 1048 2-s2.0-0015840363
32. Streeten D. H. P., Anderson G. H. Jr., Dalakos T. G., Angiotensin blockade: its clinical significance. The American Journal of Medicine 1976 60 6 817 824 2-s2.0-0017319515
33. Ogihara T., Yamamoto T., Kumahara Y., Clinical applications of synthetic angiotensin II analogue. Japanese Circulation Journal 1974 38 11 997 1003 2-s2.0-0016176049
34. Ondetti M. A., Rubin B., Cushman D. W., Design of specific inhibitors of angiotensin converting enzyme: new class of orally active antihypertensive agents. Science 1977 196 4288 441 444 2-s2.0-0017578611 (Pubitemid 8073845)
35. Ondetti M. A., Cushman D. W., Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension. Journal of Medicinal Chemistry 1981 24 4 355 361 2-s2.0-0019500685 (Pubitemid 11151637)
36. Ondetti M. A., Cushman D. W., Soffer R. L., Inhibitors of angiotensin converting enzyme. Biochemical Regulation of Blood Pressure 1981 New York, NY, USA Wiley 165 204
37. Todd P. A., Heel R. C., Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1986 31 3 198 248 2-s2.0-0022645133 (Pubitemid 16184167)
38. Todd P. A., Goa K. L., Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 1992 43 3 346 381 2-s2.0-0026594779
39. Natesh R., Schwager S. L. U., Evans H. R., Sturrock E. D., Acharya K. R., Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry 2004 43 27 8718 8724 2-s2.0-3042732126 10.1021/bi049480n (Pubitemid 38880042)
40. Bauer J. H., Angiotensin converting enzyme inhibitors. American Journal of Hypertension 1990 3 4 331 337 2-s2.0-0025309926 (Pubitemid 20215207)
41. Azizi M., Webb R., Nussberger J., Hollenberg N. K., Renin inhibition with aliskiren: where are we now, and where are we going? Journal of Hypertension 2006 24 2 243 256 2-s2.0-33644789557 10.1097/01.hjh.0000202812.72341.99 (Pubitemid 43348229)
42. Ibrahim M. M., RAS inhibition in hypertension. Journal of Human Hypertension 2006 20 2 101 108 2-s2.0-31444453963 10.1038/sj.jhh.1001960 (Pubitemid 43148610)
43. Werner C., Baumhäkel M., Teo K. K., Schmieder R., Mann J., Unger T., Yusuf S., Böhm M., RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clinical Research in Cardiology 2008 97 7 418 431 2-s2.0-47649125502 10.1007/s00392-008-0668-3
44. Maibaum J., Stutz S., Göschke R., Rigollier P., Yamaguchi Y., Cumin F., Rahuel J., Baum H. P., Cohen N. C., Schnell C. R., Fuhrer W., Gruetter M. G., Schilling W., Wood J. M., Structural modification of the P2′ position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets. Journal of Medicinal Chemistry 2007 50 20 4832 4844 2-s2.0-34848869297 10.1021/jm070316i (Pubitemid 47525468)
45. Wexler R. R., Greenlee W. J., Irvin J. D., Goldberg M. R., Prendergast K., Smith R. D., Timmermans P. B. M. W. M., Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. Journal of Medicinal Chemistry 1996 39 3 625 656 2-s2.0-0030053138 (Pubitemid 26069685)
46. Stoukides C. A., McVoy H. J., Kaul A. F., Candesartan cilexetil: an angiotensin II receptor blocker. Annals of Pharmacotherapy 1999 33 12 1287 1298 2-s2.0-0033390259 (Pubitemid 30022808)
47. Gleiter C. H., Jägle C., Gresser U., Mörike K., Candesartan. Cardiovascular Drug Reviews 2004 22 4 263 284 2-s2.0-12244268928 (Pubitemid 40116803)
48. Kjeldsen S. E., Stlhammar J., Hasvold P., Bodegard J., Olsson U., Russell D., Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. Journal of Human Hypertension 2010 24 4 263 273 2-s2.0-77949875945 10.1038/jhh.2009.77
49. Eklind-Cervenka M., Benson L., Dahlström U., Edner M., Rosenqvist M., Lund L. H., Association of candesartan vs losartan with all-cause mortality in patients with heart failure. Journal of the American Medical Association 2011 305 2 175 182 2-s2.0-78651395471 10.1001/jama.2010.1949
50. Vauquelin G., Fierens F., Liefde I. V., Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. Journal of Hypertension 2006 24 1 S23 S30 2-s2.0-33745579670 10.1097/01.hjh.0000220403.61493.18
51. Copeland R. A., The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety. Expert Opinion on Drug Discovery 2010 5 4 305 310 2-s2.0-77950197835 10.1517/17460441003677725
52. Vauquelin G., Charlton S. J., Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. British Journal of Pharmacology 2010 161 3 488 508 2-s2.0-77956309074 10.1111/j.1476-5381.2010.00936.x
53. White W. B., Weber M. A., Sica D., Bakris G. L., Perez A., Cao C., Kupfer S., Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011 57 3 413 420 2-s2.0-79953239152 10.1161/HYPERTENSIONAHA.110.163402
54. Bakris G. L., Sica D., Weber M., White W. B., Roberts A., Perez A., Cao C., Kupfer S., The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. Journal of Clinical Hypertension 2011 13 2 81 88 2-s2.0-79251590265 10.1111/j.1751-7176.2010.00425.x
55. Naik P., Murumkar P., Giridhar R., Yadav M. R., Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists-a perspective. Bioorganic and Medicinal Chemistry 2010 18 24 8418 8456 2-s2.0-78649449966 10.1016/j.bmc.2010. 10.043
56. Dahlöf B., Devereux R. B., Kjeldsen S. E., Julius S., Beevers G., De Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L. H., Nieminen M. S., Omvik P., Oparil S., Wedel H., Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359 9311 995 1003 2-s2.0-0037160968 10.1016/S0140-6736(02)08089-3 (Pubitemid 34286536)
57. Julius S., Kjeldsen S. E., Weber M., Brunner H. R., Ekman S., Hansson L., Hua T., Laragh J., McInnes G. T., Mitchell L., Plat F., Schork A., Smith B., Zanchetti A., Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 363 9426 2022 2031 2-s2.0-2942635317 10.1016/S0140-6736(04) 16451-9 (Pubitemid 38781102)
58. Fogari R., Mugellini A., Zoppi A., Derosa G., Pasotti C., Fogari E., Preti P., Influence of losartan and atenolol on memory function in very elderly hypertensive patients. Journal of Human Hypertension 2003 17 11 781 785 2-s2.0-0345307638 10.1038/sj.jhh.1001613 (Pubitemid 37441435)
59. Hansson L., Lithell H., Skoog I., Baro F., Bánki C. M., Breteler M., Carbonin P. U., Castaigne A., Correia M., Degaute J. P., Elmfeldt D., Engedal K., Farsang C., Ferro J., Hachinski V., Hofman A., James O. F. W., Krisin E., Leeman M., De Leeuw P. W., Leys D., Lobo A., Nordby G., Olofsson B., Opolski G., Prince M., Reischies F. M., Rosenfeld J. B., Ruilope L., Salerno J., Tilvis R., Trenkwalder P., Zanchetti A., Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Pressure 1999 8 3 177 183 2-s2.0-0032720579
60. Trenkwalder P., The Study on COgnition and Prognosis in the Elderly (SCOPE)-recent analyses. Journal of Hypertension 2006 24 1 S107 S114 2-s2.0-33745570098 10.1097/01.hjh.0000220415.99610.22 (Pubitemid 44336832)
61. Zanchetti A., Elmfeldt D., Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE)-a review. Blood Pressure 2006 15 2 71 79 2-s2.0-33745075280 10.1080/08037050600771583 (Pubitemid 43878912)
62. Kim K. S., Abraham D., Williams B., Violin J. D., Mao L., Rockman H. A., Beta-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. American Journal of Physiology 2012 303 H1001 H1010
63. Boerrigter G., Soergel D. G., Violin J. D., Lark M. W., Burnett J. C. Jr., TRV120027, a novel beta-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circulation: Heart Failure 2012 5 627 634
64. Kirkby N. S., Hadoke P. W. F., Bagnall A. J., Webb D. J., The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? British Journal of Pharmacology 2008 153 6 1105 1119 2-s2.0-40949132561 10.1038/sj.bjp.0707516 (Pubitemid 351415492)
65. Ruilope L. M., Dukat A., Böhm M., Lacourcière Y., Gong J., Lefkowitz M. P., Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. The Lancet 2010 375 9722 1255 1266 2-s2.0-77950628157 10.1016/S0140-6736(09)61966-8
66. Paulis L., Steckelings U. M., Unger T., Key advances in antihypertensive treatment. Nature Reviews Cardiology 2011 9 276 285
67. Paulis L., Unger T., Novel therapeutic targets for hypertension. Nature Reviews Cardiology 2010 7 8 431 441 2-s2.0-77955012886 10.1038/nrcardio.2010.85
68. Gallo-Payet N., Shum M., Baillargeon J. P., Langlois M. F., Wallinder C., Alterman M., Hallberg A., Carpentier, AC, AT2 receptor agonists: exploiting the beneficial arm of ang II signaling. Current Hypertension Reviews 2012 8 47 59
69. Yamada H., Akishita M., Ito M., Tamura K., Daviet L., Lehtonen J. Y. A., Dzau V. J., Horiuchi M., AT2 receptor and vascular smooth muscle cell differentiation in vascular development. Hypertension 1999 33 6 1414 1419 2-s2.0-0032588252 (Pubitemid 29282663)
70. Lenkei Z., Palkovits M., Corvol P., Llorens-Cortès C., Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Frontiers in Neuroendocrinology 1997 18 4 383 439 2-s2.0-0030864345 10.1006/frne.1997.0155 (Pubitemid 27463182)
71. Horiuchi M., Mogi M., Iwai M., The angiotensin II type 2 receptor in the brain. Journal of the Renin-Angiotensin-Aldosterone System 2010 11 1 1 6 2-s2.0-77749298333 10.1177/1470320309347793
72. Ichiki T., Labosky P. A., Shiota C., Okuyama S., Imagawa Y., Fogo A., Niimura F., Ichikawa I., Hogan B. L. M., Inagami T., Effects on blood pressure exploratory behaviour of mice lacking angiotensin II type 2 receptor. Nature 1995 377 6551 748 750 2-s2.0-0028858478
73. Tebbs C., Pratten M. K., Pipkin F. B., Angiotensin II is a growth factor in the peri-implantation rat embryo. Journal of Anatomy 1999 195 1 75 86 2-s2.0-0032773446 10.1017/S0021878299005191 (Pubitemid 29378197)
74. Millan M. A., Jacobowitz D. M., Aguilera G., Catt K. J., Differential distribution of AT1 and AT2 angiotensin II receptor subtypes in the rat brain during development. Proceedings of the National Academy of Sciences of the United States of America 1991 88 24 11440 11444 2-s2.0-0026357448 (Pubitemid 21916057)
75. Tsutsumi K., Saavedra J. M., Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. American Journal of Physiology 1991 261 1 R209 R216 2-s2.0-0025912598
76. Lenkei Z., Palkovits M., Corvol P., Llorens-Cortes C., Distribution of angiotensin II type-2 receptor (AT2) mRNA expression in the adult rat brain. The Journal of Comparative Neurology 1996 373 322 339 (Pubitemid 26325833)
77. Grammatopoulos T. N., Jones S. M., Ahmadi F. A., Hoover B. R., Snell L. D., Skoch J., Jhaveri V. V., Poczobutt A. M., Weyhenmeyer J. A., Zawada W. M., Angiotensin type I receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Molecular Neurodegeneration 2007 2 1, article 1 2-s2.0-34247893855 10.1186/1750-1326-2-1 (Pubitemid 46698826)
78. Argañaraz G. A., Konno A. C., Perosa S. R., Santiago J. F. C., Boim M. A., Vidotti D. B., Varella P. P. V., Costa L. G., Canzian M., Porcionatto M. A., Yacubian E. M., Sakamoto A. C., Carrete H., Centeno R. S., Amado D., Cavalheiro E. A., Silva J. A., Mazzacoratti M. D. G. N., The renin-angiotensin system is upregulated in the cortex and hippocampus of patients with temporal lobe epilepsy related to mesial temporal sclerosis. Epilepsia 2008 49 8 1348 1357 2-s2.0-48149084973 10.1111/j.1528-1167.2008.01581.x
79. Abdalla S., Lother H., El Missiry A., Langer A., Sergeev P., El Faramawy Y., Quitterer U., Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease. Journal of Biological Chemistry 2009 284 10 6554 6565 2-s2.0-65249120870 10.1074/jbc.M807746200
80. Gallo-Payet N., Guimond M. O., Bilodeau L., Wallinder C., Alterman M., Hallberg A., Angiotensin II, a neuropeptide at the frontier between endocrinology and neuroscience: is there a link between the angiotensin II type 2 receptor and Alzheimer's disease? Front Endocrinology 2011 2, article 17
81. Jing F., Mogi M., Sakata A., Iwanami J., Tsukuda K., Ohshima K., Min L. J., Steckelings U. M., Unger T., Dahlof B., Horiuchi M., Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. Journal of Cerebral Blood Flow & Metabolism 2012 32 248 255
82. Meffert S., Stoll M., Steckelings U. M., Bottari S. P., Unger T., The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Molecular and Cellular Endocrinology 1996 122 1 59 67 2-s2.0-0030606680 10.1016/0303-7207(96)03873-7 (Pubitemid 26328859)
83. Laflamme L., De Gasparo M., Gallo J. M., Payet M. D., Gallo-Payet N., Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108-15 cells. Effect counteracted by the AT1 receptors. Journal of Biological Chemistry 1996 271 37 22729 22735 2-s2.0-0029809061 10.1074/jbc.271.37.22729 (Pubitemid 26304718)
84. Lucius R., Gallinat S., Rosenstiel P., Herdegen T., Sievers J., Unger T., The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. Journal of Experimental Medicine 1998 188 4 661 670 2-s2.0-0032541392 10.1084/jem.188.4.661 (Pubitemid 28387929)
85. De Gasparo M., Catt K. J., Inagami T., Wright J. W., Unger T., International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacological Reviews 2000 52 3 415 472 2-s2.0-0033824138
86. Carey R. M., Wang Z. Q., Siragy H. M., Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000 35 1 155 163 2-s2.0-0033956854 (Pubitemid 30054167)
87. Steckelings U. M., Rompe F., Kaschina E., Namsolleck P., Grzesiak A., Funke-Kaiser H., Bader M., Unger T., The past, present and future of angiotensin II type 2 receptor stimulation. Journal of the Renin-Angiotensin-Aldosterone System 2010 11 1 67 73 2-s2.0-77749298365 10.1177/1470320309347791
88. Carey R. M., Angiotensin type-2 receptors and cardiovascular function: are angiotensin type-2 receptors protective? Current Opinion in Cardiology 2005 20 4 264 269 2-s2.0-21244505820 10.1097/01.hco.0000166596.44711.b4 (Pubitemid 40896363)
89. Savoia C., Touyz R. M., Volpe M., Schiffrin E. L., Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension 2007 49 2 341 346 2-s2.0-33846427712 10.1161/01.HYP.0000253968. 95136.b8 (Pubitemid 46143011)
90. Siragy H. M., The angiotensin II type 2 receptor and the kidney. Journal of the Renin-Angiotensin-Aldosterone System 2010 11 1 33 36 2-s2.0-77749289280 10.1177/1470320309347786
91. Unger T., Targeting cardiovascular protection: the concept of dual renin-angiotensin system control. MedGenMed Medscape General Medicine 2008 10, article S4 2-s2.0-42549170264
92. Lemarié C. A., Schiffrin E. L., The angiotensin II type 2 receptor in cardiovascular disease. Journal of the Renin-Angiotensin-Aldosterone System 2010 11 1 19 31 2-s2.0-77749273905 10.1177/1470320309347785
93. Steckelings U. M., Kaschina E., Unger T., The AT2 receptor-a matter of love and hate. Peptides 2005 26 8 1401 1409 2-s2.0-22544448655 10.1016/j.peptides.2005.03.010 (Pubitemid 41021474)
94. Wan Y., Wallinder C., Plouffe B., Beaudry H., Mahalingam A. K., Wu X., Johansson B., Holm M., Botoros M., Karlén A., Pettersson A., Nyberg F., Fändriks L., Gallo-Payet N., Hallberg A., Alterman M., Design, synthesis, and biological evaluation, of the first selective nonpeptide AT2 receptor agonist. Journal of Medicinal Chemistry 2004 47 24 5995 6008 2-s2.0-8644281991 10.1021/jm049715t (Pubitemid 39507341)
95. Wu X., Wan Y., Mahalingam A. K., Murugaiah A. M. S., Plouffe B., Botros M., Karlén A., Hallberg M., Gallo-Payet N., Alterman M., Selective angiotensin II AT2 receptor agonists: arylbenzylimidazole structure-activity relationships. Journal of Medicinal Chemistry 2006 49 24 7160 7168 2-s2.0-33845362252 10.1021/jm0606185 (Pubitemid 44886001)
96. Murugaiah A. M. S., Wallinder C., Mahalingam A. K., Wu X., Wan Y., Plouffe B., Botros M., Karlén A., Hallberg M., Gallo-Payet N., Alterman M., Selective angiotensin II AT2 receptor agonists devoid of the imidazole ring system. Bioorganic and Medicinal Chemistry 2007 15 22 7166 7183 2-s2.0-34548849480 10.1016/j.bmc.2007.07.026 (Pubitemid 47451779)
97. Kivlighn S. D., Huckle W. R., Zingaro G. J., Rivero R. A., Lotti V. J., Chang R. S. L., Schorn T. W., Kevin N., Johnson R. G., Greenlee W. J., Siegl P. K. S., Discovery of L-162,313: a nonpeptide that mimics the biological actions of angiotensin II. American Journal of Physiology 1995 268 3 R820 R823 2-s2.0-0028928407
98. Mertens B., Vanderheyden P., Michotte Y., Sarre S., Direct angiotensin II type 2 receptor stimulation decreases dopamine synthesis in the rat striatum. Neuropharmacology 2010 58 7 1038 1044 2-s2.0-77950955706 10.1016/j.neuropharm. 2010.01.009
99. Mogi M., Horiuchi M., Effect of angiotensin II type 2 receptor on stroke, cognitive impairment and neurodegenerative diseases. Geriatric Gerontology. In press
100. Kaschina E., Grzesiak A., Li J., Foryst-Ludwig A., Timm M., Rompe F., Sommerfeld M., Kemnitz U. R., Curato C., Namsolleck P., Tschöpe C., Hallberg A., Alterman M., Hucko T., Paetsch I., Dietrich T., Schnackenburg B., Graf K., Dahlöf B., Kintscher U., Unger T., Steckelings U. M., Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 2008 118 24 2523 2532 2-s2.0-58149375072 10.1161/CIRCULATIONAHA.108.784868
101. Rompe F., Artuc M., Hallberg A., Alterman M., Ströder K., Thöne-Reineke C., Reichenbach A., Schacherl J., Dahlöf B., Bader M., Alenina N., Schwaninger M., Zuberbier T., Funke-Kaiser H., Schmidt C., Schunck W. H., Unger T., Steckelings U. M., Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor b. Hypertension 2010 55 4 924 931 2-s2.0-77950472601 10.1161/HYPERTENSIONAHA.109.147843
102. Rehman A., Leibowitz A., Yamamoto N., Rautureau Y., Paradis P., Schiffrin, EL, Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2012 59 291 299
103. Foulquier S., Steckelings U. M., Unger T., Impact of the AT(2) receptor agonist C21 on blood pressure and beyond. Current Hypertension Reports 2012 14 5 403 409
104. Shraim N., Mertens B., Clinckers R., Sarre S., Michotte Y., Van Eeckhaut A., Microbore liquid chromatography with UV detection to study the in vivo passage of compound 21, a non-peptidergic AT2 receptor agonist, to the striatum in rats. Journal of Neuroscience Methods 2011 202 137 142 2-s2.0-79959974494 10.1016/j.jneumeth.2011.06.009
105. Spinifex EMA401 meets primary endpoint in phase 2 trail. Pharmaceutical Business Review 2012 London, UK Progressive Media Group
106. Braszko J. J., Kupryszewski G., Witczuk B., Wisniewski K., Angiotensin II-(3-8)-hexapeptide affects motor activity, performance of passive avoidance and a conditioned avoidance response in rats. Neuroscience 1988 27 3 777 783 2-s2.0-0024202954 (Pubitemid 19025386)
107. Lee J., Albiston A. L., Allen A. M., Mendelsohn F. A. O., Ping S. E., Barrett G. L., Murphy M., Morris M. J., Mcdowall S. G., Chai S. Y., Effect of I.C.V. injection of AT4 receptor ligands, NLE 1-angiotensin IV and LVV-hemorphin 7, on spatial learning in rats. Neuroscience 2004 124 2 341 349 2-s2.0-10744221634 10.1016/j.neuroscience.2003.12.006 (Pubitemid 38229654)
108. Wright J. W., Clemens J. A., Panetta J. A., Smalstig E. B., Weatherly L. S., Kramár E. A., Pederson E. S., Mungall B. H., Harding J. W., Effects of LY231617 and angiotensin IV on ischemia-induced deficits in circular water maze and passive avoidance performance in rats. Brain Research 1996 717 1-2 1 11 2-s2.0-0029929215 10.1016/0006-8993(95)01454-3 (Pubitemid 26155069)
109. Wright J. W., Stubley L., Pederson E. S., Kramár E. A., Hanesworth J. M., Harding J. W., Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. Journal of Neuroscience 1999 19 10 3952 3961 2-s2.0-0033562659 (Pubitemid 29222269)
110. Braszko J. J., Wielgat P., Walesiuk A., Effect of D3 dopamine receptors blockade on the cognitive effects of angiotensin IV in rats. Neuropeptides 2008 42 3 301 309 2-s2.0-44649113091 10.1016/j.npep.2008.02.001
111. Lee J., Mustafa T., McDowall S. G., Mendelsohn F. A. O., Brennan M., Lew R. A., Albiston A. L., Chai S. Y., Structure-activity study of LVV-hemorphin-7: angiotensin AT4 receptor ligand and inhibitor of insulin-regulated aminopeptidase. Journal of Pharmacology and Experimental Therapeutics 2003 305 1 205 211 2-s2.0-0037380026 10.1124/jpet.102.045492 (Pubitemid 36373852)
112. Chai S. Y., Yeatman H. R., Parker M. W., Ascher D. B., Thompson P. E., Mulvey H. T., Albiston A. L., Development of cognitive enhancers based on inhibition of insulin-regulated aminopeptidase. BMC Neuroscience 2008 9 2, article S14 2-s2.0-57449086119 10.1186/1471-2202-9-S2-S14
113. Albiston A. L., Diwakarla S., Fernando R. N., Mountford S. J., Yeatman H. R., Morgan B., Pham V., Holien J. K., Parker M. W., Thompson P. E., Chai S. Y., Identification and development of specific inhibitors for insulin-regulated aminopeptidase as a new class of cognitive enhancers. British Journal of Pharmacology 2011 164 1 37 47 2-s2.0-79961241498 10.1111/j.1476-5381.2011.01402. x
114. Wright J. W., Harding J. W., Brain renin-angiotensin-A new look at an old system. Progress in Neurobiology 2011 95 1 49 67 2-s2.0-79960675107 10.1016/j.pneurobio.2011.07.001
115. Birks J., Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006 1 CD005593 2-s2.0-33645524717
116. Cosman K. M., Boyle L. L., Porsteinsson A. P., Memantine in the treatment of mild-to-moderate Alzheimer's disease. Expert Opinion on Pharmacotherapy 2007 8 2 203 214 2-s2.0-33846804155 10.1517/14656566.8.2.203 (Pubitemid 46206622)
117. Doraiswamy P. M., Xiong G. L., Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opinion on Pharmacotherapy 2006 7 1 1 10 2-s2.0-30344479822 10.1517/14656566.7.1.1 (Pubitemid 43056417)
118. Raina P., Santaguida P., Ismaila A., Patterson C., Cowan D., Levine M., Booker L., Oremus M., Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Annals of Internal Medicine 2008 148 5 379 397 2-s2.0-41049111771 (Pubitemid 351665469)
119. Swanson G. N., Hanesworth J. M., Sardinia M. F., Coleman J. K. M., Wright J. W., Hall K. L., Miller-Wing A. V., Stobb J. W., Cook V. I., Harding E. C., Harding J. W., Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regulatory Peptides 1992 40 3 409 419 2-s2.0-0026806962 10.1016/0167-0115(92)90527-2
120. Harding J. W., Cook V. I., Miller-Wing A. V., Hanesworth J. M., Sardinia M. F., Hall K. L., Stobb J. W., Swanson G. N., Coleman J. K. M., Wright J. W., Harding E. C., Identification of an AII (3-8) [AIV] binding site in guinea pig hippocampus. Brain Research 1992 583 1-2 340 343 2-s2.0-0026680189
121. De Gasparo M., Husain A., Alexander W., Catt K. J., Chiu A. T., Drew M., Goodfriend T., Harding J. W., Inagami T., Timmermans P. B. M. W. M., Proposed update of angiotensin receptor nomenclature. Hypertension 1995 25 5 924 927 2-s2.0-0029004647
122. Sardinia M. F., Hanesworth J. M., Krebs L. T., Harding J. W., AT4 receptor binding characteristics: D-Amino acid- and glycine-substituted peptides. Peptides 1993 14 5 949 954 2-s2.0-0027330018 10.1016/0196-9781(93) 90071-N
123. Sardinia M. F., AT4 receptor Structure-Binding relationship: N-terminal-modified angiotensin IV analogues. Peptides 1994 15 8 1399 1406 2-s2.0-0028173398 10.1016/0196-9781(94)90115-5 (Pubitemid 24381186)
124. Krishnan R., Hanesworth J. M., Wright J. W., Harding J. W., Structure-binding studies of the adrenal AT4 receptor: analysis of position two- and three-modified angiotensin IV analogs. Peptides 1999 20 8 915 920 2-s2.0-0032842332 10.1016/S0196-9781(99)00081-9 (Pubitemid 29418025)
125. Krebs L. T., Kramár E. A., Hanesworth J. M., Sardinia M. F., Ball A. E., Wright J. W., Harding J. W., Characterization of the binding properties and physiological action of divalinal-angiotensin IV, a putative AT4 receptor
126. Kramár E. A., Armstrong D. L., Ikeda S., Wayner M. J., Harding J. W., Wright J. W., The effects of angiotensin IV analogs on long-term potentiation within the CA1 region of the hippocampus in vitro. Brain Research 2001 897 1-2 114 121 2-s2.0-0035815529 10.1016/S0006-8993(01)02100-X (Pubitemid 32244358)
127. Kobori T., Goda K., Sugimoto K., Ota T., Tomisawa K., Preparation of peptide derivatives as angiotensin IV receptor agonists. 1997, WO 97/03093 A1
128. Kobori T., Goda K., Sugimoto K., Ota T., Tomisawa K., Preparation of amino acid derivatives as angiotensin IV receptor agonists. 1998, WO 98/05624 A1
129. Albiston A. L., McDowall S. G., Matsacos D., Sim P., Clune E., Mustafa T., Lee J., Mendelsohn F. A. O., Simpson R. J., Connolly L. M., Chai S. Y., Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase. Journal of Biological Chemistry 2001 276 52 48623 48626 2-s2.0-0035966085 10.1074/jbc.C100512200
130. Wolfe M. S., Therapeutic strategies for Alzheimer's disease. Nature Reviews Drug Discovery 2002 1 11 859 866 2-s2.0-0036833437 10.1038/nrd938 (Pubitemid 37361581)
131. Hallberg M., Targeting the insulin-regulated aminopeptidase/AT4 receptor for cognitive disorders. Drug News and Perspectives 2009 22 3 133 139 2-s2.0-67449101063 10.1358/dnp.2009.22.3.1325032
132. Gard P. R., Cognitive-enhancing effects of angiotensin IV. BMC Neuroscience 2008 9 2, article S15 2-s2.0-57449120247 10.1186/1471-2202-9-S2-S15
133. Wright J. W., Harding J. W., The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease. Journal of the Renin-Angiotensin-Aldosterone System 2008 9 4 226 237 2-s2.0-66149108067 10.1177/1470320308099084
134. De Bundel D., Smolders I., Vanderheyden P., Michotte Y., Ang II and Ang IV: unraveling the mechanism of action on synaptic plasticity, memory, and epilepsy. CNS Neuroscience and Therapeutics 2008 14 4 315 339 2-s2.0-56049111427 10.1111/j.1755-5949.2008.00057.x
135. Tsujimoto M., Mizutani S., Adachi H., Kimura M., Nakazato H., Tomoda Y., Identification of human placental leucine aminopeptidase as oxytocinase. Archives of Biochemistry and Biophysics 1992 292 2 388 392 2-s2.0-0026570567 10.1016/0003-9861(92)90007-J
136. Rogi T., Tsujimoto M., Nakazato H., Mizutani S., Tomoda Y., Human placental leucine aminopeptidase/oxytocinase: a new member of type II membrane-spanning zinc metallopeptidase family. Journal of Biological Chemistry 1996 271 1 56 61 2-s2.0-0030049295
137. Rasmussen T. E., Pedraza-Diaz S., Hardre R., Laustsen P. G., Carrion A. G., Kristensen T., Structure of the human oxytocinase/insulin-regulated aminopeptidase gene and localization to chromosome 5q21. European Journal of Biochemistry 2000 267 8 2297 2306 2-s2.0-0034049408 10.1046/j.1432-1327.2000. 01234.x (Pubitemid 30220076)
138. Keller S. R., Scott H. M., Mastick C. C., Aebersold R., Lienhard G. E., Cloning and characterization of a novel insulin-regulated membrane aminopeptidase from Glut4 vesicles. Journal of Biological Chemistry 1995 270 40 23612 23618 2-s2.0-0028817838 10.1074/jbc.270.40.23612
139. Laustsen P. G., Vang S., Kristensen T., Mutational analysis of the active site of human insulin-regulated aminopeptidase. European Journal of Biochemistry 2001 268 1 98 104 2-s2.0-0035173732 10.1046/j.1432-1327.2001.01848. x (Pubitemid 32052252)
140. Laustsen P. G., Rasmussen T. E., Petersen K., Pedraza-Diaz S., Moestrup S. K., Gliemann J., Sottrup-Jensen L., Kristensen T., The complete amino acid sequence of human placental oxytocinase. Biochimica et Biophysica Acta 1997 1352 1 1 7 2-s2.0-0030988029 10.1016/S0167-4781(97)00036-5 (Pubitemid 27195956)
141. Albiston A. L., Peck G. R., Yeatman H. R., Fernando R., Ye S., Chai S. Y., Therapeutic targeting of insulin-regulated aminopeptidase: heads and tails? Pharmacology and Therapeutics 2007 116 3 417 427 2-s2.0-36148987224 10.1016/j.pharmthera.2007.07.006 (Pubitemid 350116937)
142. Ito K., Nakajima Y., Onohara Y., Takeo M., Nakashima K., Matsubara F., Ito T., Yoshimoto T., Crystal structure of aminopeptidase N (Proteobacteria alanyl aminopeptidase) from Escherichia coli and conformational change of methionine 260 involved in substrate recognition. Journal of Biological Chemistry 2006 281 44 33664 33676 2-s2.0-33845954688 10.1074/jbc.M605203200 (Pubitemid 46036745)
143. Tholander F., Muroya A., Roques B. P., Fournié-Zaluski M. C., Thunnissen M. M. G. M., Haeggström J. Z., Structure-based dissection of the active site chemistry of leukotriene A4 hydrolase: implications for M1 aminopeptidases and inhibitor design. Chemistry and Biology 2008 15 9 920 929 2-s2.0-51849151991 10.1016/j.chembiol.2008.07.018
144. Luciani N., Marie-Claire C., Ruffet E., Beaumont A., Roques B. P., Fournié-Zaluski M. C., Characterization of Glu350 as a critical residue involved in the N-terminal amine binding site of aminopeptidase N (EC 3.4.11.2): insights into its mechanism of action. Biochemistry 1998 37 2 686 692 2-s2.0-0032512368 10.1021/bi971705p (Pubitemid 28123803)
145. Ye S., Chai S. Y., Lew R. A., Albiston A. L., Insulin-regulated aminopeptidase: analysis of peptide substrate and inhibitor binding to the catalytic domain. Biological Chemistry 2007 388 4 399 403 2-s2.0-34047182553 10.1515/BC.2007.044 (Pubitemid 46514689)
146. Ye S., Chai S. Y., Lew R. A., Ascher D. B., Morton C. J., Parker M. W., Albiston A. L., Identification of modulating residues defining the catalytic cleft of insulin-regulated aminopeptidase. Biochemistry and Cell Biology 2008 86 3 251 261 2-s2.0-44949104409 10.1139/O08-037 (Pubitemid 351810525)
147. Matsumoto H., Rogi T., Yamashiro K., Kodama S., Tsuruoka N., Hattori A., Takio K., Mizutani S., Tsujimoto M., Characterization of a recombinant soluble form of human placental leucine aminopeptidase/oxytocinase expressed in Chinese hamster ovary cells. European Journal of Biochemistry 2000 267 1 46 52 2-s2.0-0033958063 10.1046/j.1432-1327.2000.00949.x (Pubitemid 30029736)
148. Wallis M. G., Lankford M. F., Keller S. R., Vasopressin is a physiological substrate for the insulin-regulated aminopeptidase IRAP. American Journal of Physiology 2007 293 4 E1092 E1102 2-s2.0-35148832135 10.1152/ajpendo.00440.2007 (Pubitemid 47535842)
149. Albiston A. L., Mustafa T., McDowall S. G., Mendelsohn F. A. O., Lee J., Chai S. Y., AT4 receptor is insulin-regulated membrane aminopeptidase: potential mechanisms of memory enhancement. Trends in Endocrinology and Metabolism 2003 14 2 72 77 2-s2.0-0038407755 10.1016/S1043-2760(02)00037-1 (Pubitemid 36733919)
150. Chai S. Y., Fernando R., Peck G., Ye S. Y., Mendelsohn F. A. O., Jenkins T. A., Albiston A. L., The angiotensin IV/AT4 receptor. Cellular and Molecular Life Sciences 2004 61 21 2728 2737 2-s2.0-11144314693 10.1007/s00018-004-4246-1 (Pubitemid 40022434)
151. Kovacs G. L., De Wied D., Peptidergic modulation of learning and memory processes. Pharmacological Reviews 1994 46 3 269 291 2-s2.0-0027984807 (Pubitemid 24310131)
152. Alescio-Lautier B., Paban V., Soumireu-Mourat B., Neuromodulation of memory in the hippocampus by vasopressin. European Journal of Pharmacology 2000 405 1-3 63 72 2-s2.0-0034730432 10.1016/S0014-2999(00)00542-2
153. Gulpinar M. A., Yegen B. C., The physiology of learning and memory: role of peptides and stress. Current Protein & Peptide Science 2004 5 457 473 (Pubitemid 39555457)
154. Albiston A. L., Fernando R. N., Yeatman H. R., Burns P., Ng L., Daswani D., Diwakarla S., Pham V., Chai S. Y., Gene knockout of insulin-regulated aminopeptidase: loss of the specific binding site for angiotensin IV and age-related deficit in spatial memory. Neurobiology of Learning and Memory 2010 93 1 19 30 2-s2.0-74649085115 10.1016/j.nlm.2009.07.011
155. Einstein E. B., Patterson C. A., Hon B. J., Regan K. A., Reddi J., Melnikoff D. E., Mateer M. J., Schulz S., Johnson B. N., Tallent M. K., Somatostatin signaling in neuronal cilia is critical for object recognition memory. Journal of Neuroscience 2010 30 12 4306 4314 2-s2.0-77949816722 10.1523/JNEUROSCI.5295-09.2010
156. Fernando R. N., Albiston A. L., Chai S. Y., The insulin-regulated aminopeptidase IRAP is colocalised with GLUT4 in the mouse hippocampus-potential role in modulation of glucose uptake in neurones? European Journal of Neuroscience 2008 28 3 588 598 2-s2.0-47849111875 10.1111/j.1460-9568.2008. 06347.x (Pubitemid 352040410)
157. Vanderheyden P. M. L., From angiotensin IV binding site to AT4 receptor. Molecular and Cellular Endocrinology 2009 302 2 159 166 2-s2.0-62949248271 10.1016/j.mce.2008.11.015
158. Garreau I., Chansel D., Vandermeersch S., Fruitier I., Piot J. M., Ardaillou R., Hemorphins inhibit angiotensin IV binding and interact with aminopeptidase N. Peptides 1998 19 8 1339 1348 2-s2.0-0031764635 10.1016/S0196-9781(98)00075-8 (Pubitemid 28514438)
159. Demaegdt H., Lenaerts P. J., Swales J., De Backer J. P., Laeremans H., Le M. T., Kersemans K., Vogel L. K., Michotte Y., Vanderheyden P., Vauquelin G., Angiotensin AT4 receptor ligand interaction with cystinyl aminopeptidase and aminopeptidase N: [125I]Angiotensin IV only binds to the cystinyl aminopeptidase apo-enzyme. European Journal of Pharmacology 2006 546 1-3 19 27 2-s2.0-33748317951 10.1016/j.ejphar.2006.07.005 (Pubitemid 44331842)
160. Wright J. W., Yamamoto B. J., Harding J. W., Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets. Progress in Neurobiology 2008 84 2 157 181 2-s2.0-39049161519 10.1016/j.pneurobio.2007.10.009
161. Yamamoto B. J., Elias P. D., Masino J. A., Hudson B. D., McCoy A. T., Anderson Z. J., Varnum M. D., Sardinia M. F., Wright J. W., Harding J. W., The angiotensin IV analog Nle-Tyr-Leu- ψ -(CH2-NH 2)3-4-His-Pro-Phe (Norleual) can act as a hepatocyte growth factor/c-met inhibitor. Journal of Pharmacology and Experimental Therapeutics 2010 333 1 161 173 2-s2.0-77949692477 10.1124/jpet.109.161711
162. Wright J. W., Harding J. W., The brain angiotensin IV/AT4 receptor system as a new target for the treatment of Alzheimer's disease. Drug Development Research 2009 70 7 472 480 2-s2.0-70649099207 10.1002/ddr.20328
163. McCoy A., Pharmacokinetic characterization of angiotensin IV analogs with therapeutic potential for cancer and dementia [thesis from Department of Veterinary and Comparative Anatomy, Pharmacology, and Physiology] 2010 Washington, DC, USA Washington State University
164. Lew R. A., Mustafa T., Ye S., McDowall S. G., Chai S. Y., Albiston A. L., Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP). Journal of Neurochemistry 2003 86 2 344 350 2-s2.0-0037817386 10.1046/j.1471-4159.2003.01852.x (Pubitemid 36842433)
165. Demaegdt H., Laeremans H., De Backer J. P., Mosselmans S., Le M. T., Kersemans V., Michotte Y., Vauquelin G., Vanderheyden P. M. L., Synergistic modulation of cystinyl aminopeptidase by divalent cation chelators. Biochemical Pharmacology 2004 68 5 893 900 2-s2.0-3843132896 10.1016/j.bcp.2004.05.046 (Pubitemid 39044517)
166. Laeremans H., Demaegdt H., De Backer J. P., Le M. T., Kersemans V., Michotte Y., Vauquelin G., Vanderheyden P. M. L., Metal ion modulation of cystinyl aminopeptidase. Biochemical Journal 2005 390 1 351 357 2-s2.0-23944432904 10.1042/BJ20050349 (Pubitemid 41192262)
167. Demaegdt H., Lukaszuk A., De Buyser E., De Backer J. P., Szemenyei E., Tóth G., Chakravarthy S., Panicker M., Michotte Y., Tourwé D., Vauquelin G., Selective labeling of IRAP by the tritiated AT4 receptor ligand [3H]Angiotensin IV and its stable analog [3H]AL-11. Molecular and Cellular Endocrinology 2009 311 1-2 77 86 2-s2.0-69249232045 10.1016/j.mce.2009.07.020
168. Lukaszuk A., Demaegdt H., Szemenyei E., Tóth G., Tymecka D., Misicka A., Karoyan P., Vanderheyden P., Vauquelin G., Tourwé D., β -homo-amino acid scan of angiotensin IV. Journal of Medicinal Chemistry 2008 51 7 2291 2296 2-s2.0-41849106437 10.1021/jm701490g (Pubitemid 351503284)
169. Yang R., Smolders I., De Bundel D., Fouyn R., Halberg M., Demaegdt H., Vanderheyden P., Dupont A. G., Brain and peripheral angiotensin II type 1 receptors mediate renal vasoconstrictor and blood pressure responses to angiotensin IV in the rat. Journal of Hypertension 2008 26 5 998 1007 2-s2.0-42049085291 10.1097/HJH.0b013e3282f5ed58 (Pubitemid 351520988)
170. Lukaszuk A., Demaegdt H., Feytens D., Vanderheyden P., Vauquelin G., Tourwé D., The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues. Journal of Medicinal Chemistry 2009 52 18 5612 5618 2-s2.0-70349200782 10.1021/jm900651p
171. Chen H., Roques B. P., Fournié-Zaluski M. C., Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorganic and Medicinal Chemistry Letters 1999 9 11 1511 1516 2-s2.0-0033532555 10.1016/S0960-894X(99)00219-X (Pubitemid 29274187)
172. Demaegdt H., De Backer J. P., Lukaszuk A., Tóth G., Szemenyei E., Tourwé D., Vauquelin G., Angiotensin IV displays only low affinity for native insulin-regulated aminopeptidase (IRAP). Fundamental and Clinical Pharmacology 2012 26 194 197 2-s2.0-79953784620 10.1111/j.1472-8206.2011.00948.x
173. Demaegdt H., Smitz L., De Backer J. P., Le M. T., Bauwens M., Szemenyei E., Tóth G., Michotte Y., Vanderheyden P., Vauquelin G., Translocation of the insulin-regulated aminopeptidase to the cell surface: detection by radioligand binding. British Journal of Pharmacology 2008 154 4 872 881 2-s2.0-44949219130 10.1038/bjp.2008.117 (Pubitemid 351821580)
174. Axén A., Andersson H., Lindeberg G., Rönnholm H., Kortesmaa J., Demaegdt H., Vauquelin G., Karlén A., Hallberg M., Small potent ligands to the insulin-regulated aminopeptidase (IRAP)/AT4 receptor. Journal of Peptide Science 2007 13 7 434 444 2-s2.0-34447563925 10.1002/psc.859 (Pubitemid 47082893)
175. Ascher D. B., Cromer B. A., Morton C. J., Volitakis I., Cherny R. A., Albiston A. L., Chai S. Y., Parker M. W., Regulation of insulin-regulated membrane aminopeptidase activity by its C-terminal domain. Biochemistry 2011 50 13 2611 2622 2-s2.0-79953166764 10.1021/bi101893w
176. Lukaszuk A., Demaegdt H., van den Eynde I., Vanderheyden P., Vauquelin G., Tourwé D., Conformational constraints in angiotensin IV to probe the role of Tyr2, Pro5 and Phe6. Journal of Peptide Science 2011 17 8 545 553 2-s2.0-79960408853 10.1002/psc.1365
177. Andersson H., Demaegdt H., Vauquelin G., Lindeberg G., Karlén A., Hallberg M., Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2. Bioorganic and Medicinal Chemistry 2008 16 14 6924 6935 2-s2.0-47349126657 10.1016/j.bmc.2008.05.046
178. Axén A., Lindeberg G., Demaegdt H., Vauquelin G., Karlén A., Hallberg M., Cyclic insulin-regulated aminopeptidase (IRAP)/AT4 receptor ligands. Journal of Peptide Science 2006 12 11 705 713 2-s2.0-33750738879 10.1002/psc.782 (Pubitemid 44697843)
179. Andersson H., Demaegdt H., Johnsson A., Vauquelin G., Lindeberg G., Hallberg M., Erdélyi M., Karlén A., Hallberg A., Potent macrocyclic inhibitors of insulin-regulated aminopeptidase (IRAP) by olefin ring-closing metathesis. Journal of Medicinal Chemistry 2011 54 11 3779 3792 2-s2.0-79958153974 10.1021/jm200036n
180. Andersson H., Demaegdt H., Vauquelin G., Lindeberg G., Karlén A., Hallberg M., Erdélyi M., Hallberg A., Disulfide cyclized tripeptide analogues of angiotensin IV as potent and selective inhibitors of insulin-regulated aminopeptidase (IRAP). Journal of Medicinal Chemistry 2010 53 22 8059 8071 2-s2.0-78649500321 10.1021/jm100793t
181. Schmidt B., Lindman S., Tong W., Lindeberg G., Gogoll A., Lai Z., Thörnwall M., Synnergren B., Nilsson A., Welch C. J., Sohtell M., Westerlund C., Nyberg F., Karlén A., Hallberg A., Design, synthesis, and biological activities of four angiotensin II receptor ligands with γ -turn mimetics replacing amino acid residues 3-5. Journal of Medicinal Chemistry 1997 40 6 903 919 2-s2.0-15144349952 10.1021/jm960553d (Pubitemid 27131620)
182. Lindman S., Lindeberg G., Gogoll A., Nyberg F., Karlén A., Hallberg A., Synthesis, receptor binding affinities and conformational properties of cyclic methylenedithioether analogues of angiotensin II. Bioorganic and Medicinal Chemistry 2001 9 3 763 772 2-s2.0-0035106848 10.1016/S0968-0896(00)00294-7 (Pubitemid 32215242)
183. Marsault E., Peterson M. L., Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. Journal of Medicinal Chemistry 2011 54 7 1961 2004 2-s2.0-79953777824 10.1021/jm1012374
184. Driggers E. M., Hale S. P., Lee J., Terrett N. K., The exploration of macrocycles for drug discovery-An underexploited structural class. Nature Reviews Drug Discovery 2008 7 7 608 624 2-s2.0-46449115901 10.1038/nrd2590 (Pubitemid 351927725)
185. Thunnissen M. M. G. M., Nordlund P., Haeggström J. Z., Crystal structure of human leukotriene A4 hydrolase, a bifunctional enzyme in inflammation. Nature Structural Biology 2001 8 2 131 135 2-s2.0-0035146853 10.1038/84117 (Pubitemid 32117699)
186. Albiston A. L., Morton C. J., Hooi L. N., Pham V., Yeatman H. R., Ye S., Fernando R. N., De Bundel D., Ascher D. B., Mendelsohn F. A. O., Parker M. W., Siew Y. C., Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase. FASEB Journal 2008 22 12 4209 4217 2-s2.0-57349101001 10.1096/fj.08-112227
187. Albiston A. L., Pham V., Ye S., Ng L., Lew R. A., Thompson P. E., Holien J. K., Morton C. J., Parker M. W., Chai S. Y., Phenylalanine-544 plays a key role in substrate and inhibitor binding by providing a hydrophobic packing point at the active site of insulin-regulated aminopeptidase. Molecular Pharmacology 2010 78 4 600 607 2-s2.0-77957220424 10.1124/mol.110.065458